Disease · MONDO_0005351
Comparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 23
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Olanzapine vs Placebo: deaths from any cause | 0 of 75 | 0 of 77 | 152 | NCT01170117 | Trial comparisons |
| Olanzapine vs Placebo: serious adverse events | 16 of 75 | 13 of 77 | 152 | NCT01170117 | Trial comparisons |
| Physiologic Estrogen Replacement vs Placebo: serious adverse events | 12 of 55 | 16 of 55 | 110 | NCT00088153 | Trial comparisons |
| Testosterone vs Placebo: deaths from any cause | 0 of 43 | 0 of 47 | 90 | NCT01121211 | Trial comparisons |
| Testosterone vs Placebo: serious adverse events | 4 of 43 | 1 of 47 | 90 | NCT01121211 | Trial comparisons |
| Active vs Placebo: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT00310791 | Trial comparisons |
| Rh IGF-1 + Transdermal Estradiol vs Placebo + Transdermal Estradiol: deaths from any cause | 0 of 38 | 0 of 37 | 75 | NCT01301183 | Trial comparisons |
| Rh IGF-1 + Transdermal Estradiol vs Placebo + Transdermal Estradiol: serious adverse events | 7 of 38 | 12 of 37 | 75 | NCT01301183 | Trial comparisons |
| Setraline vs Placebo: serious adverse events | 0 of 20 | 0 of 16 | 36 | NCT01996644 | Trial comparisons |
| Placebo Plus Day Hospital vs Olanzapine Plus Day Hospital: serious adverse events | 0 of 18 | 0 of 16 | 34 | NCT00260962 | Trial comparisons |
| Denosumab (0-12 months) followed by alendronate (12-24 months) vs Placebo (0-12 months) followed by alendronate (12-24 months): deaths from any cause | 0 of 20 | 0 of 10 | 30 | NCT03292146 | Trial comparisons |
| Denosumab (0-12 months) followed by alendronate (12-24 months) vs Placebo (0-12 months) followed by alendronate (12-24 months): serious adverse events | 0 of 20 | 0 of 10 | 30 | NCT03292146 | Trial comparisons |
| Active Romosozumab 210mg Injection vs Placebo: deaths from any cause | 0 of 20 | 0 of 10 | 30 | NCT04779216 | Trial comparisons |
| Active Romosozumab 210mg Injection vs Placebo: serious adverse events | 0 of 20 | 0 of 10 | 30 | NCT04779216 | Trial comparisons |
| PUFA vs Placebo: deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT01933243 | Trial comparisons |
| PUFA vs Placebo: serious adverse events | 0 of 12 | 0 of 12 | 24 | NCT01933243 | Trial comparisons |
| Olanzapine vs Placebo: deaths from any cause | 0 of 11 | 0 of 12 | 23 | NCT00692185 | Trial comparisons |
| Olanzapine vs Placebo: serious adverse events | 0 of 11 | 0 of 12 | 23 | NCT00692185 | Trial comparisons |
| Teriparatide vs Placebo: serious adverse events | 2 of 12 | 3 of 11 | 23 | NCT00759772 | Trial comparisons |
| Quetiapine vs Placebo: deaths from any cause | 0 of 6 | 0 of 9 | 15 | NCT00518973 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005351/comparisons